FDA approves rare blood cancer drug

According to Reuters, the US Food and Drug Administration has approved a rare blood cancer drug called Besponsa.

The drug was produced by big pharma company Pfizer Inc. Besponsa will be used to treat adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (ALL).

This type of cancer causes bone marrow to produce too many B-Cell lymphocytes, an immature white blood cell.

Besponsa is a targeted therapy that binds to B-cell ALL cancer cells that expresses the CD22 antigen, blocking the growth of cancer cells.